In Vivo Generation of CAR-T & NK cells Using an Engineered Lentiviral Vector
Time: 4:00 pm
day: Day Two, Non-Tracked PM
Details:
• Specific targeting of CD7 cells in vivo creates CAR-T and NK cells
• CD20 targeted for B-cell malignancies
• CD19 targeted for autoimmune applications
• Clinical entry Q424 for CD20 program
